2006
DOI: 10.1200/jco.2006.07.0250
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Our study shows that newly diagnosed HER-2-overexpressing breast cancer patients are at increased risk for brain metastases. Because most brain metastases occur after the development of systemic disease, these findings prompt consideration of brain prophylaxis strategies with HER-2-inhibiting small molecules able to cross the blood-brain barrier and/or radiologic screening to detect asymptomatic brain metastases.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

9
191
0
4

Year Published

2009
2009
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 292 publications
(204 citation statements)
references
References 35 publications
9
191
0
4
Order By: Relevance
“…Several studies demonstrated increased risk of brain relapse in breast cancer patients with overexpressed or amplified HER2-neu gene [5][6][7][8]. HER2 abnormalities occur in 20-30% of invasive breast cancers and are associated with more aggressive tumor growth, increased risk of relapse and shorter survival [9,10].…”
Section: Introductionmentioning
confidence: 99%
“…Several studies demonstrated increased risk of brain relapse in breast cancer patients with overexpressed or amplified HER2-neu gene [5][6][7][8]. HER2 abnormalities occur in 20-30% of invasive breast cancers and are associated with more aggressive tumor growth, increased risk of relapse and shorter survival [9,10].…”
Section: Introductionmentioning
confidence: 99%
“…9,10 Amplified HER2 gene or overexpressed HER2 protein is observed in approximately 15-30% of primary breast cancers and these patients showed short survival or poor prognosis. [11][12][13] Trastuzumab is a humanized mouse monoclonal antibody that binds to the extracellular domain of the HER2 molecule. 14 It has been clinically approved as the world's first humanized monoclonal antibody breast cancer therapeutic agent in 1998 by the US Food and Drug Administration (FDA), and it was subsequently approved in Japan for use in a metastatic setting in 2001 and in an adjuvant setting in 2008.…”
Section: Resultsmentioning
confidence: 99%
“…Triple-negative tumor status (ER-/PR-/HER2-), ER-, PR-, and basal-like tumors also were associated with an increased risk of brain metastasis [153,175,187,193,195,216,219,221,230]. Brain metastasis as the first site of metastasis developed quickly and most frequently in breast cancer patients with HER2 and triple-negative tumors [153,231].…”
Section: Risk Factorsmentioning
confidence: 98%
“…Slimane et al [216] found lung metastasis as the first site of relapse and negative hormone receptor status risk factors for brain metastasis in breast cancer patients, although other studies included young age, tumor size, stage, tumor grade, histology, and human epidermal growth factor receptor 2 (HER2, also known as neu) [187,193,[217][218][219][220][221]. Overexpression of HER2 is repeatedly supported as a risk factor for brain metastasis in breast cancer patients [57,175,193,221,222], and the risk has increased since the development of trastuzumab (Herceptin; Genentech, San Francisco, CA), a monoclonal antibody therapy [57].…”
Section: Risk Factorsmentioning
confidence: 99%
See 1 more Smart Citation